Certified by Founder Lodge
Artios
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $115,000,000
0 Participating Investments
-
Founded date
2015
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| November, 18 ,2025 | Series D | $115,000,000 |
SV Health Investors
Andera Partners
Omega Funds
EQT Life Sciences
IP Group plc
Janus Henderson Investors
Avidity Partners
Invus
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
FOVC | $2,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Project Eleven | $20,000,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)